Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids

Background. Since 1997 diphtheria-tetanus toxoids-acellular pertussis (DTaP) vaccines have been recommended for the five dose pertussis vaccination series. To assess rates of medically attended injection site reactions (ISRs), seizures, allergic responses and febrile episodes after Tripedia DTaP vaccine administered in the context of routine care, we conducted a retrospective assessment among the population of Group Health Cooperative from 1997 through 2000. Methods. Administrative databases were used to identify medical visits linked with diagnostic codes potentially indicative of ISRs, seizures, allergic responses and febrile episodes after DTaP vaccine. Outcomes were confirmed by medical record review. Results. During the study period 76 133 doses of DTaP were administered. Of the 26 ISRs identified, 6 followed DTaP given as the fourth dose and 18 followed DTaP given as the fifth dose, for rates of 1 per 2779 and 1 per 900 vaccinations, respectively. During the study period nearly all children receiving DTaP as the fifth dose had received whole cell pertussis vaccine for their primary series, and all of the fifth dose ISRs were among that group. Four of those reactions involved the entire upper arm. The rate of febrile seizures within 2 days of DTaP among children <2 years of age was 1 per 19 496 vaccinations. Conclusions. The low rate of febrile seizures and other serious events confirms the safety of DTaP vaccine. The risk of medically attended ISRs was highest with DTaP given as the fifth dose, and whole arm reactions were reported, but medically attended ISRs were relatively uncommon and were self-limited.

[1]  R. Chen,et al.  Combination vaccines: postlicensure safety evaluation. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J. Liese,et al.  Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age , 2001, The Pediatric infectious disease journal.

[3]  S. Halperin,et al.  Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. , 2001, Vaccine.

[4]  V. Pankratz,et al.  Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study. , 2001, Vaccine.

[5]  S. Salmaso,et al.  Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines. , 2001, Pediatrics.

[6]  Robert T. Chen,et al.  Infant Immunization With Acellular Pertussis Vaccines in the United States: Assessment of the First Two Years' Data From the Vaccine Adverse Event Reporting System (VAERS) , 2000, Pediatrics.

[7]  M. Pichichero,et al.  Extensive Swelling After Booster Doses of Acellular Pertussis–Tetanus–Diphtheria Vaccines , 2000, Pediatrics.

[8]  M. Pichichero,et al.  Safety and Immunogenicity of Six Acellular Pertussis Vaccines and One Whole-Cell Pertussis Vaccine Given as a Fifth Dose in Four- to Six-Year-Old Children , 2000, Pediatrics.

[9]  M. Gold,et al.  A comparison of serious adverse reactions to whole cell and acellular pertussis vaccines in South Australia , 1999, The Medical journal of Australia.

[10]  M. Pichichero,et al.  A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. , 1997, Pediatrics.

[11]  M. Knuf,et al.  Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. , 1997, The Journal of pediatrics.

[12]  B. Schwartz,et al.  Acellular pertussis vaccine: recommendations for use as the initial series in infants and children. American Academy of Pediatrics Committee on Infectious Diseases. , 1997, Pediatrics.

[13]  M. Gahr,et al.  Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. , 1996, The Journal of pediatrics.

[14]  S. Rosenthal,et al.  The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment. , 1996, Archives of pediatrics & adolescent medicine.

[15]  H. Hallander,et al.  A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. , 1996, The New England journal of medicine.

[16]  D Greco,et al.  A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. , 1996, The New England journal of medicine.

[17]  S. Halperin,et al.  Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. , 1995, The Pediatric infectious disease journal.

[18]  A. Colville,et al.  A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines , 1995, The Lancet.

[19]  E. Rothstein,et al.  Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants. , 1994, Pediatrics.

[20]  M. Pichichero,et al.  Comparison of 13 acellular pertussis vaccines: adverse reactions. , 1993, Pediatrics.

[21]  A. Frank,et al.  Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children. , 1993, American journal of diseases of children.

[22]  M. Pichichero,et al.  Acellular pertussis vaccination of 2-month-old infants in the United States. , 1992, Pediatrics.

[23]  M. Pichichero,et al.  Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children. , 1992, American journal of diseases of children.

[24]  J. Mezzatesta,et al.  Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody. , 1990, The Journal of pediatrics.

[25]  R. Thompson,et al.  Neurologic events following diphtheria-tetanus-pertussis immunization. , 1988, Pediatrics.

[26]  J. Cherry,et al.  Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. , 1981, Pediatrics.

[27]  Hodes,et al.  The Risk of Seizures After Receipt of Whole-Cell Pertussis or Measles , Mumps , and Rubella Vaccine , 2001 .

[28]  Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2000, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[29]  S. M. Hewitt,et al.  Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 1997, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[30]  H. Fineberg,et al.  Adverse Effects of Pertussis and Rubella Vaccines , 1991 .

[31]  K. Reisinger,et al.  Comparison of Acellular and Whole-Cell Pertussis-Component DTP Vaccines: A Multicenter Double-blind Study in 4- to 6-Year-Old Children , 1990 .